Rituximab in haematology and oncology in 10 years of experience

Anna Wache; Lidia Gil; Mieczysław Komarnicki

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2008
vol. 12

Send email

Copy url:

abstract:

Rituximab in haematology and oncology in 10 years of experience

Anna Wache

,

Lidia Gil

,

Mieczysław Komarnicki

Współczesna Onkologia (2008) vol. 12; 4 (173-178)

Online publish date: 2008/07/22

View full text Get citation

Rituximab, a chimeric anti-CD20 monoclonal antibody, used as a single agent or in combination with chemotherapy, has resulted in significant responses in patients with almost every subtype of B-cell lymphoma. Its modulation effects on the immune system have prompted its use in non-neoplastic diseases. Here, based on 10 years of experience, we summarize label and off-label use of rituximab in oncology and haematology. Rituximab mechanisms of action and resistance are discussed.

keywords:

Rituximab in haematology and oncology in 10 years of experience

Anna Wache , Lidia Gil , Mieczysław Komarnicki

rituximab, B-cell lymphoma, autoimmune haematological disorders

Anna Wache

,

Lidia Gil

,

Mieczysław Komarnicki